Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. by Erika Kroll (20537020)

Effects of the presence of stabilimentum concerning prey vibration acting in the direction tangent to the spiral threads. by G. Greco (7636232)

Seven forecast scenarios. by Ryan P. Thombs (9138968)

Subjects:

Forecast for each scenario, 2023-2032. by Ryan P. Thombs (9138968)

Subjects:

Overview of the WeARTolerance program. by Ana Beato (20489933)

“…<div><p>The stigma surrounding mental health remains a significant barrier to help-seeking and well-being in youth populations. …”

Data Extraction Sheet: A sheet that contains the data that we extracted from the included studies. by Mohamed R. Abdelraouf (21501468)

Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

“…By comparing samples from NAFLD patients and healthy controls, we identified 1,770 significant DEGs, with 1,073 being upregulated and 697 downregulated. …”

Key significant pathways in the final models of self-compassion. by Eriko Takahashi (22608061)

Subjects:

Significant Decrease in Vessel Count of Trade Vessels in (a) Bosporus Strait and (b) Bab el-Mandeb Strait. by Cherryl Chico (20978829)

Univariable and multivariable analyses (age-adjusted), concerning a selection of medicaments p < 0.1 and n ≥ 10. by P.G.J. ter Horst (21743830)

Univariable and multivariable analyses (age- and abstinence days-adjusted), concerning medicament(s) use and Low Semen Quality (LSQ). by P.G.J. ter Horst (21743830)